Drugs for hypertriglyceridemia

Medical Letter on Drugs and Therapeutics

Volumn 55, Issue 1411, 2013, Pages 17-19

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; CHOLESTEROL; CHOLINE FENOFIBRATE; CYCLOSPORIN A; DOCOSAHEXAENOIC ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL;

BLURRED VISION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLELITHIASIS; DRUG DOSAGE FORM COMPARISON; DRUG WITHDRAWAL; DRY EYE; DYSLIPIDEMIA; FATIGUE; FLUSHING; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HEPATITIS; HEPATOMEGALY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPIGMENTATION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; LETTER; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS (TOPIC); MYOSITIS; PANCREATITIS; PEPTIC ULCER; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SIDE EFFECT; XANTHOMA;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; FIBRIC ACIDS; FISH OILS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; NIACIN; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84874749100     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (14)

1. M Miller et al. Triglycerides and cardiovascular disease. A scientific statement from the American Heart Association. Circulation 2011; 123:2292.
2. Drugs for lipids. Treat Guidel Med Lett 2011; 9:13.
3. L Berglund et al. Evaluation and treatment of hypertriglyc- eridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97: 2969.
4. MH Frick et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coro- nary heart disease. N Engl J Med 1987; 317:1237.
5. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102:21.
6. Fenofibric acid (Trilipix). Med Lett Drugs Ther 2009; 51:33.
7. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563.
8. E Bruckert et al. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and athero- sclerosis. Atherosclerosis 2010; 210:353.
9. AIM-HIGH Investigators. Niacin in patients with low HDL cho- lesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255.
10. GISSI-Prevenzione Investigators. Dietary supplementation with n- 3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354:447.
11. M Yokoyama et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369:1090.
12. D Kromhout et al. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363:2015.
13. SM Kwak et al. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the sec- ondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Int Med 2012; 172:686.
14. Fish oil supplements. Med Lett Drugs Ther 2012; 54:83.